AlphaGrep UK
BCRX icon

AlphaGrep UK’s BioCryst Pharmaceuticals BCRX Stock Holding History

AlphaGrep UK’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$100K Buy
+11,972
New +$113K 0.03% 720

Other funds holding BCRX

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
JHC
Jones Hill Capital New York $589M AUM
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 31.32% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
Jupiter Asset Management
Jupiter Asset Management London, United Kingdom $21.4B AUM 19.74% 1-Year Est. Return

AlphaGrep UK's BCRX Position: Q3 2026 in Review

AlphaGrep UK opened a new position in BioCryst Pharmaceuticals (BCRX) in Q3 2026: 11,972 shares worth $100K. The stake represents 0.03% of the portfolio and ranks #720 among its holdings.

241 funds tracked by Wall St. Rank hold BCRX as of Q3 2026.

  • AlphaGrep UK held 11,972 shares of BioCryst Pharmaceuticals worth $100K as of Q3 2026.
  • BioCryst Pharmaceuticals was a new AlphaGrep UK position in Q3 2026.
  • BioCryst Pharmaceuticals made up 0.03% of AlphaGrep UK's portfolio in Q3 2026, its #720 holding.
  • 241 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q3 2026.

Based on AlphaGrep UK's 13F filing for Q3 2026, filed 12 Nov 2026.